Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screeningLorenzo Turcano, Andrea Ilari, Esther Torrente et al.|PLoS neglected tropical diseases|2018Cited by 68
NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington's disease mouse modelDaniele Moretti, Alberto Bresciani, Licia Tomei et al.|Free Radical Biology and Medicine|2020Cited by 49
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)Alberto Bresciani, Larry C. Park, Antonino Missineo et al.|Archives of Biochemistry and Biophysics|2017Cited by 45
Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interactionStefania Colarusso, Elisabetta Bianchi, Daniele De Simone et al.|Bioorganic & Medicinal Chemistry|2020Cited by 27
Spiro-containing derivatives show antiparasitic activity against Trypanosoma brucei through inhibition of the trypanothione reductase enzymeLorenzo Turcano, Alberto Bresciani, Theo Battista et al.|PLoS neglected tropical diseases|2020Cited by 21